Softwr

Healthcare · head to head

Lunit vs SilverCloud by Amwell

Lunit logo

Lunit

Healthcare

FDA cleared and CE marked AI for mammography, tomosynthesis and chest radiography

From
On request
Rated
-
Full reviewWebsite
SilverCloud by Amwell logo

SilverCloud by Amwell

Healthcare

Guided digital cognitive behavioural therapy with a published randomised trial evidence base

From
On request
Rated
-
Full reviewWebsite

The short version

  • Each has a real cost: Lunit the regulatory permission differs by product and by region, and INSIGHT Risk has been filed with the FDA but not cleared, so a buyer who reads a corporate press release rather than the specific clearance for their product and jurisdiction will plan a deployment they cannot legally run.; SilverCloud by Amwell the evidence base is for the guided model, and organisations that deploy SilverCloud as unstaffed self service get the completion rates of unguided self help, which is not what the trials measured.
  • They diverge on capability: Lunit covers Lunit INSIGHT MMG, SilverCloud by Amwell covers Guided programmes.
  • Prices and features above were last checked on 1 September 2026.

Where they differ

Only the attributes on which Lunit and SilverCloud by Amwell actually diverge.

Attributes where Lunit and SilverCloud by Amwell differ
AttributeLunitSilverCloud by Amwell
PlatformsWebWeb, iOS, Android

Identical on both: starting price (On request), pricing model (quote), free tier (No), user rating (Not yet rated), category (Healthcare).

What each one covers

Drawn from each product's published feature list. An absence here means we hold no record of it - not that the product lacks it.

Only in Lunit

  • Lunit INSIGHT MMG
  • Lunit INSIGHT DBT
  • Lunit INSIGHT CXR
  • Volpara density assessment
  • Volpara RiskPathways
  • Volpara dose tracking
  • PACS and mammography workstation integration

Only in SilverCloud by Amwell

  • Guided programmes
  • Supporter review
  • Symptom measurement
  • Clinician dashboard
  • Risk detection
  • NHS talking therapies alignment
  • Multiple deployment models

What people use each for

The jobs each tool is most often brought in to do.

Lunit

  • A national breast screening programme evaluating AI as a second reader to reduce double reading workload where two human readers are currently mandatednot SilverCloud by Amwell
  • A breast centre that moved to tomosynthesis and now has reading times it cannot staff, wanting detection support on DBT specificallynot SilverCloud by Amwell
  • An American breast imaging centre needing automated volumetric density assessment to meet patient density notification requirements, which is what Volpara is bought fornot SilverCloud by Amwell
  • A tuberculosis or lung screening programme in a high volume, radiologist scarce setting using chest radiography triage to prioritise filmsnot SilverCloud by Amwell

SilverCloud by Amwell

  • An NHS talking therapies service needing a digital option that fits national reporting requirements and reduces waiting list pressure for step two interventionsnot Lunit
  • A health plan wanting a digital mental health offering it can defend to a clinical governance committee with peer reviewed trial evidencenot Lunit
  • A university counselling service facing demand it cannot staff, using guided digital cognitive behavioural therapy as a first stepnot Lunit
  • An employer that wants an evidence based clinical intervention rather than a wellbeing content librarynot Lunit

Where each one falls short

Documented limitations, not opinions. Every one is a constraint you would hit in normal use.

Lunit

  • The regulatory permission differs by product and by region, and INSIGHT Risk has been filed with the FDA but not cleared, so a buyer who reads a corporate press release rather than the specific clearance for their product and jurisdiction will plan a deployment they cannot legally run.
  • Detection AI changes recall rates in screening, and the downstream cost of additional diagnostic workup lands on the programme rather than on the software budget, which is the cost most screening business cases omit.
  • Performance is sensitive to the mammography vendor and acquisition protocol, so published results from a Hologic estate do not transfer to a GE or Siemens estate without local validation the buyer must fund.
  • MMG, DBT and CXR are licensed separately and Volpara modules are separate again, so a breast centre wanting detection, density and risk pathways is assembling four line items rather than buying one product.
  • Using AI as a replacement for one of two human readers is a workforce and liability decision that regulators and professional bodies treat differently in each country, so the saving that justifies the purchase may not be permitted where you operate.

SilverCloud by Amwell

  • The evidence base is for the guided model, and organisations that deploy SilverCloud as unstaffed self service get the completion rates of unguided self help, which is not what the trials measured.
  • Supporter capacity is normally the buyer responsibility rather than part of the licence, so the real cost includes trained staff time that does not appear on the software quote.
  • Digital cognitive behavioural therapy has substantial dropout across all vendors, so a service planning capacity from enrolment numbers rather than completion numbers will overstate the throughput gained.
  • It is now sold as part of the Amwell portfolio, and Amwell has restructured its product lines since acquiring SilverCloud, so buyers should ask how SilverCloud is positioned within the Amwell Converge platform and whether it can still be bought standalone.
  • Guided digital cognitive behavioural therapy is a step two intervention and does not serve moderate to severe presentations, so a service that buys it without a funded escalation pathway simply relocates the queue.

Pricing, plan by plan

Lunit

On request
  • Lunit INSIGHT$undefined/year
    • Priced per study or per annual examination volume by product
    • MMG, DBT and CXR licensed separately
    • Volpara density and RiskPathways modules quoted separately

SilverCloud by Amwell

On request
  • SilverCloud by Amwell$undefined/year
    • Priced per member per month or per completed course depending on the buyer type
    • Supporter capacity is usually provided by the buyer, not included in the licence
    • Programme library scope affects the rate

Which should you pick?

Choose Lunit if

  • You need lunit insight mmg.
  • You also want lunit insight dbt.
Lunit review

Choose SilverCloud by Amwell if

  • You need guided programmes.
  • You work on Web, iOS, Android.
  • You also want supporter review.
SilverCloud by Amwell review

Questions people ask

Is Lunit or SilverCloud by Amwell better?
Neither clearly leads. Lunit starts at On request and SilverCloud by Amwell at On request, and user ratings are close enough to be indistinguishable. Choose on capability and platform support.
Which is cheaper, Lunit or SilverCloud by Amwell?
Lunit starts at On request and SilverCloud by Amwell at On request.
Does Lunit or SilverCloud by Amwell run on more platforms?
Lunit runs on Web. SilverCloud by Amwell runs on Web, iOS, Android.
What is Lunit best used for?
Lunit is most often used for a national breast screening programme evaluating ai as a second reader to reduce double reading workload where two human readers are currently mandated, a breast centre that moved to tomosynthesis and now has reading times it cannot staff, wanting detection support on dbt specifically, an american breast imaging centre needing automated volumetric density assessment to meet patient density notification requirements, which is what volpara is bought for, a tuberculosis or lung screening programme in a high volume, radiologist scarce setting using chest radiography triage to prioritise films. Of those, a national breast screening programme evaluating ai as a second reader to reduce double reading workload where two human readers are currently mandated and a breast centre that moved to tomosynthesis and now has reading times it cannot staff, wanting detection support on dbt specifically are not what SilverCloud by Amwell is typically brought in for.
What can Lunit do that SilverCloud by Amwell cannot?
Lunit covers Lunit INSIGHT MMG, Lunit INSIGHT DBT, Lunit INSIGHT CXR, Volpara density assessment. SilverCloud by Amwell covers Guided programmes, Supporter review, Symptom measurement, Clinician dashboard.

Answered from the vendors’ own pages

Lunit: Is Lunit FDA cleared?

Yes for specific products. INSIGHT MMG, INSIGHT DBT and INSIGHT CXR Triage hold FDA 510(k) clearances. INSIGHT Risk, the five year risk prediction model, has been filed but was not cleared at the time of writing.

SilverCloud by Amwell: Is SilverCloud still available under its own name?

Yes. It is marketed as SilverCloud by Amwell and has its own product pages and NHS partnership, though contracting runs through Amwell.

Lunit: Can Lunit replace a second human reader in screening?

That depends entirely on your jurisdiction and professional body guidance, not on the software. The CE mark permits clinical use; it does not authorise a workforce model.

SilverCloud by Amwell: What evidence supports it?

It has been evaluated in independently led randomised controlled trials, including a National Institute of Mental Health funded study published in Nature Human Behaviour in 2026 examining prevalence of mental disorders over two years at scale.

Lunit: What did the Volpara acquisition add?

Volumetric breast density measurement, dose tracking and RiskPathways high risk programme management, which are the things American breast centres buy for density notification compliance rather than for detection.

SilverCloud by Amwell: Do we need to provide the supporters?

In most deployments, yes. The guided model requires trained supporter time, and that staffing is usually the buyer responsibility rather than included in the licence.

Lunit: Is pricing published?

No. It is quoted per study or per annual volume, by product, with on premises and cloud priced differently.

SilverCloud by Amwell: Is it suitable for severe presentations?

No. It is a step two style intervention for mild to moderate presentations, and it needs a funded escalation pathway for anything more severe.

Share

Related pages

More on Lunit

More on SilverCloud by Amwell

Keep looking

Other head to heads